Evaluation of antibacterial peptide eye drops
Early Phase 1
Recruiting
- Conditions
- Bacterial keratitis.Keratitis
- Registration Number
- IRCT20181229042160N4
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients with bacterial keratitis caused by Staphylococcus aureus or Pseudomonas aeruginosa
Having consent to enter the study
Exclusion Criteria
The patient's lack of consent to continue the examinations
Occurrence of any unusual side effects
Infectious keratitis of fungal origin
Spread of infection to other parts of the eye
Having systemic immunodeficiency
Having a cornea transplant
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Keratitis infection. Timepoint: 3, 7, and 14 days after drug administration. Method of measurement: Microscopic evaluation using Slit lamp.;Treatment duration. Timepoint: 3, 7, and 14 days after drug administration. Method of measurement: Microscopic evaluation using Slit lamp.
- Secondary Outcome Measures
Name Time Method Corneal opacity. Timepoint: 7, 14, 30 and 90 days. Method of measurement: Microscopic evaluation using Slit lamp.;Pain and burning. Timepoint: 7, 14, 30 and 90 days. Method of measurement: Microscopic evaluation using Slit lamp.;Shedding tears. Timepoint: Macroscopic and microscopic evaluation using Slit lamp. Method of measurement: 7, 14, 30 and 90 days.;Eye redness. Timepoint: 7, 14, 30 and 90 days. Method of measurement: Macroscopic and microscopic evaluation using Slit lamp.;Eye inflammation. Timepoint: 7, 14, 30 and 90 days. Method of measurement: Microscopic evaluation using slit lamp.